Drugs - Xagena.net - Update in Medicine

Search results for "Alemtuzumab"

Chronic lymphocytic leukaemia, screen for hepatitis B virus before treatment with Ofatumumab

Ofatumumab ( Arzerra ) is indicated for the treatment of chronic lymphocytic leukaemia in patients who are refractory to Fludarabine and Alemtuzumab. Ofatumumab is a monocolonal antibody that acts ag ... read article

Multiple sclerosis: European Commission has approved Lemtrada

Genzyme has announced that the European Commission ( EC ) has granted marketing authorization for Lemtrada ( Alemtuzumab ). Lemtrada is indicated for the treatment of adult patients with relapsing re ... read article

NICE does not recommend Ofatumumab as a treatment for refractory chronic lymphocytic leukaemia

The NICE ( National Institute for Health and Clinical Excellence ) has published three separate pieces of guidance for the NHS ( National Health Service ) on the use of the cancer drugs Ofatumumab ( A ... read article

Ofatumumab: high response rates in patients with Fludarabine- and Alemtuzumab-refractory chronic lymphocytic leukemia

The study enrolled patients with chronic lymphocytic leukemia ( CLL ), heavily pre-treated, who did not respond to, or who were ineligible for, currently available treatment options such as Fludarabin ... read article

Consolidation therapy following chemoimmunotherapy in B-cell chronic lymphocytic leukaemia: infection-related deaths reported with the use of MabCampath

Bayer HealthCare and Genzyme, in collaboration with Health Canada, informed of important safety information regarding the use of MabCampath ( Alemtuzumab ) as consolidation therapy following combinati ... read article

Focus

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ... read article

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ... read article

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems know ... read article

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a UC San Francisco researcher, Carlo Maley, points to a possible explanation, with the discovery that A ... read article

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ... read article

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults and some adolescents with giant cell tumor of the bone ( GCTB ), a rare and usually non-cancerous t ... read article

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Thoracic Societ ... read article

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new ... read article